Pombiliti + Opfolda
Amicus Therapeutics Announces FDA Approval and Launch of New Treatment for Pompe Disease
September 28, 2023 10:41 ET | Amicus Therapeutics, Inc.
Pombiliti™ (cipaglucosidase alfa-atga) + Opfolda™ (miglustat) Approved in ERT-Experienced Adults First and Only Two-Component Therapy for Eligible Adults Living with Late-onset Pompe Disease Amicus...
Amicus-logo.jpg
Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2023
September 01, 2023 07:00 ET | Amicus Therapeutics, Inc.
PHILADELPHIA, Sept. 01, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in upcoming presentations at the following investor conferences...
Amicus-logo.jpg
Amicus Therapeutics Announces Presentation and Posters at the SSIEM Annual Symposium 2023
August 29, 2023 07:00 ET | Amicus Therapeutics, Inc.
PHILADELPHIA, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced that one oral presentation and five posters across its development programs will be included at...
Amicus-logo.jpg
Amicus Therapeutics Appoints Simon Harford as Chief Financial Officer
August 21, 2023 07:00 ET | Amicus Therapeutics, Inc.
Daphne Quimi to Retire At Year End PHILADELPHIA, Aug. 21, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on developing and...
Amicus-logo.jpg
Amicus Therapeutics Announces Approval and Launch of New Pompe Disease Therapy in the United Kingdom
August 15, 2023 07:00 ET | Amicus Therapeutics, Inc.
Pombiliti® (cipaglucosidase alfa) + Opfolda® (miglustat) Approved for Adults Living with Late-Onset Pompe Disease in Great Britain National Institute for Health and Care Excellence (NICE) Issues...
Amicus-logo.jpg
Amicus Therapeutics Announces Second Quarter 2023 Financial Results and Corporate Updates
August 08, 2023 07:00 ET | Amicus Therapeutics, Inc.
1H 2023 Revenue Growth of 16% at CER to $180.8M Raising FY 2023 Galafold® Revenue Growth Guidance to 14%-18% at CER EU Launch of Pombiliti® + Opfolda® Underway; U.S. and U.K. Approvals Expected 3Q...
Amicus-logo.jpg
Amicus Therapeutics to Announce Second Quarter 2023 Financial Results on August 8, 2023
July 31, 2023 07:00 ET | Amicus Therapeutics, Inc.
PHILADELPHIA, July 31, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Tuesday, August 8, 2023, at...
Amicus-logo.jpg
Amicus Therapeutics Announces Approval and Launch of New Pompe Disease Therapy in the European Union
June 27, 2023 07:00 ET | Amicus Therapeutics, Inc.
PHILADELPHIA, June 27, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for...
Amicus-logo.jpg
Amicus Therapeutics Announces First Quarter 2023 Financial Results and Corporate Updates
May 10, 2023 07:00 ET | Amicus Therapeutics, Inc.
1Q23 Revenue Growth of 14% at CER to $86.3M On Track to Deliver Full-Year 2023 Galafold Revenue Growth of 12%-17% at CER U.S. FDA Pre-approval Inspection...
Amicus-logo.jpg
Amicus Therapeutics to Present at the Bank of America 2023 Health Care Conference
May 02, 2023 07:00 ET | Amicus Therapeutics, Inc.
PHILADELPHIA, May 02, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in a fireside chat at the Bank of America 2023 Health Care...